FDA committee to discuss adverse effects of testosterone products
July 17, 2014 at 14:15 PM EDT
July 17 (Reuters) - The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy.
